Journey Medical's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Journey Medical's ROA in the second quarter of 2026?
Journey Medical Corp recorded a cumulative net loss of $-6 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -6.61%.

However, within the Healthcare sector 270 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3223, from total ROA ranking in the first quarter of 2026 at 3864.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	21.42 %	7.86 %	18.04 %	32.81 %	24.26 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-10	-11	-9	-9
Return On Assets (TTM)	-6.61 %	-10.9 %	-13.24 %	-10.47 %	-11.28 %
DERM's Total Ranking	# 3223	# 3864	# 3299	# 3344	# 3365
Total Assets (TTM) in million	98	91	94	85	81
Seq. Total Assets Change	7.56 %	-3.21 %	11.08 %	5.01 %	-4.46 %
Seq. Net Income Change	-	-	-	-	-

DERM's 5 Years Annual ROA >> Back to DERM Management Effectiveness >> Compare DERM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 93
Sector	# 271
Overall	# 3035

Return On Assets Statistics
High	Average	Low
51.68 %	-20.3 %	-57.14 %
(Mar 31 2015)		(Jun 30 2018)

Financial Statements
Journey Medical's Assets	$ 98 million	DERM's Balance sheet
Journey Medical's Income	$ 0 million	Quarterly DERM's Income Statement
DERM's Income by Division		See DERM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	18.04 %	4.15 %	-26.92 %	8.1 %	-71.75 %
Total Assets in million	94	80	77	105	97
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-11	-15	-4	-30	-44
Annual Return On Assets	-12.1 %	-18.33 %	-5.01 %	-28.17 %	-45.22 %

DERM's 5 Years Annual ROA >> Back to DERM Management Effectiveness >> Compare DERM ROA to its Competitors

More Return On Assets Ratios
DERM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DERM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DERM's Competitors
Subscribers only: Roa for Journey Medical's Suppliers
Subscribers only: Return On Assets for DERM's Customers

You may also want to know
DERM's Roi	DERM's Inventory Turnover Ratio	DERM's Growth Rates	DERM's Dividend Comparisons
	DERM's Profitability Ratios	DERM's Asset Turnover Ratio	DERM's Dividend Growth
DERM's Roe	DERM's Valuation Ratios	DERM's Financial Strength Ratios	DERM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T10:11:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.